|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 221.72 USD | -0.47% |
|
+10.80% | +651.85% |
| 10-29 | Merck to boost next decade revenue forecast on new drugs optimism | RE |
| 10-29 | Merck tops third-quarter estimates as Keytruda, Gardasil outperform | RE |
Company Valuation: Moderna, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 102,976 | 69,006 | 37,919 | 16,001 | 11,523 | 88,519 | - | - |
| Change | - | -32.99% | -45.05% | -57.8% | -27.99% | 668.21% | - | - |
| Enterprise Value (EV) 1 | 92,848 | 59,104 | 29,315 | 8,976 | 5,724 | 84,605 | 86,090 | 86,456 |
| Change | - | -36.34% | -50.4% | -69.38% | -36.23% | 1,378.15% | 1.75% | 0.42% |
| P/E | 8.98x | 8.93x | -8.07x | -4.48x | -4.06x | -26.1x | -45.3x | -74.5x |
| PBR | 7.24x | 3.7x | 2.74x | 1.46x | 1.33x | 15.4x | 22x | 29.1x |
| PEG | - | -0.3x | 0x | 0.2x | 0.2x | -1.5x | 1.1x | 1.9x |
| Capitalization / Revenue | 5.58x | 3.58x | 5.54x | 4.94x | 5.93x | 42.1x | 36.2x | 26.5x |
| EV / Revenue | 5.03x | 3.07x | 4.28x | 2.77x | 2.94x | 40.3x | 35.2x | 25.9x |
| EV / EBITDA | 6.86x | 6.05x | -8.1x | -2.39x | -2x | -26.1x | -49.3x | -89.7x |
| EV / EBIT | 6.98x | 6.27x | -6.92x | -2.28x | -1.86x | -24.2x | -42.3x | -70.4x |
| EV / FCF | 6.96x | 12.9x | -7.66x | -2.21x | -2.77x | -29.3x | -58.4x | -68.1x |
| FCF Yield | 14.4% | 7.75% | -13% | -45.2% | -36.1% | -3.42% | -1.71% | -1.47% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 | -8.496 | -4.897 | -2.977 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18,471 | 19,263 | 6,848 | 3,236 | 1,944 | 2,102 | 2,444 | 3,342 |
| EBITDA 1 | 13,528 | 9,768 | -3,618 | -3,756 | -2,859 | -3,237 | -1,748 | -963.8 |
| EBIT 1 | 13,296 | 9,420 | -4,239 | -3,945 | -3,074 | -3,490 | -2,034 | -1,228 |
| Net income 1 | 12,202 | 8,362 | -4,714 | -3,561 | -2,822 | -3,369 | -1,935 | -1,200 |
| Net Debt 1 | -10,128 | -9,902 | -8,604 | -7,025 | -5,799 | -3,913 | -2,428 | -2,063 |
| Reference price 2 | 253.98 | 179.62 | 99.45 | 41.58 | 29.49 | 221.72 | 221.72 | 221.72 |
| Nbr of stocks (in thousands) | 405,450 | 384,180 | 381,284 | 384,818 | 390,734 | 399,236 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 14/02/25 | 13/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -26.1x | 40.25x | -26.13x | -.--% | 88.52B | |
| 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | |
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | |
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | |
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | |
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | |
| Average | 25.31x | 10.68x | 15.14x | 1.81% | 435.04B | |
| Weighted average by Cap. | 36.00x | 9.48x | 20.98x | 1.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MRNA Stock
- Valuation Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
